KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Moderna (MRNA) Leases (2018 - 2025)

Moderna (MRNA) has disclosed Leases for 8 consecutive years, with $719.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 5.27% to $719.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $719.0 million, a 5.27% decrease, with the full-year FY2025 number at $719.0 million, down 5.27% from a year prior.
  • Leases was $719.0 million for Q4 2025 at Moderna, up from $47.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $1.2 billion in Q3 2022 to a low of $47.0 million in Q3 2025.
  • A 5-year average of $418.2 million and a median of $431.5 million in 2024 define the central range for Leases.
  • Peak YoY movement for Leases: soared 1904.05% in 2021, then plummeted 90.56% in 2025.
  • Moderna's Leases stood at $142.0 million in 2021, then fell by 14.79% to $121.0 million in 2022, then surged by 489.26% to $713.0 million in 2023, then increased by 6.45% to $759.0 million in 2024, then fell by 5.27% to $719.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Leases are $719.0 million (Q4 2025), $47.0 million (Q3 2025), and $750.0 million (Q2 2025).